Effect of body mass index and ertapenem versus cefotetan prophylaxis on surgical site infection in elective colorectal surgery

Surgical Infections

Volumn 9, Issue 2, 2008, Pages 131-137

  Itani, Kamal M F ^a,c   Jensen, Erin H ^b   Finn, Tyler S ^b   Tomassini, Joanne E ^b   Abramson, Murray A ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c VABHCS ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFOTETAN; ERTAPENEM;

ADULT; AGED; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLORECTAL SURGERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTIVE SURGERY; FEMALE; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURGICAL INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTIC PROPHYLAXIS; BETA-LACTAMS; BODY MASS INDEX; CEFOTETAN; COLON; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; RECTUM; RETROSPECTIVE STUDIES; SURGICAL WOUND INFECTION;

EID: 42449106470     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2007.034     Document Type: Article

References (26)

1. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006;355:763-778.
2. U.S. Centers for Disease Control and Prevention. Overweight and Obesity: Obesity Trends: U.S. Obesity Trends 1985-2005. 2006. Available at http://www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/index.htm
3. World Health Organization. Obesity: Preventing and managing the global epidemic. Geneva, Switzerland: WHO. 2000;894:i-xii, 1-253.
4. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis 1997;25:112-118.
5. Cheymol G. Effects of obesity on pharmacokinetics: Implications for drug therapy. Clin Pharmacokinet 2000;39:215-231.
6. Siu D. Weighing in on antibiotic dosing of obese patients. Drug Ther Top 2006;35:9-14.
7. Scher KS. Studies on the duration of antibiotic administration for surgical prophylaxis. Am Surg 1997;63:59-62.
8. Jimenez JC, Wilson SE. Prophylaxis of infection for elective colorectal surgery. Surg Infect 2003;4:273-280.
9. Cheadle WG. Risk factors for surgical site infection. Surg Infect 2006;7(Suppl 1):S7-S11.
10. Vilar-Compte D, Mohar A, Sandoval S, et al. Surgical site infections at the National Cancer Institute in Mexico: A case-control study. Am J Infect Control 2000;28:14-20.
11. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis 2006;6:438-446.
12. Bearden DT, Rodvold KA. Dosage adjustments for antibacterials in obese patients: Applying clinical pharmacokinetics. Clin Pharmacokinet 2000;38:415-426.
13. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998;54:621-625.
14. Traynor AM, Nafziger AN, Bertino JS. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 1995;39:545-548.
15. Sanchez-Recio MM, Colino CI, Sanchez-Navarro A. A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin. J Antimicrob Chemother 2000;45:321-328.
16. Mann HJ, Buchwald H. Cefamandole distribution in serum, adipose tissue, and wound drainage in morbidly obese patients. Drug Intell Clin Pharm 1986;20:869-873.
17. Forse RA, Karam B, MacLean LD, et al. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 1989;106:750-756.
18. Zelenitsky SA, Ariano RE, Harding GK, et al. Antibiotic pharmacodynamics in surgical prophylaxis: An association between intraoperative antibiotic concentrations and efficacy. Antimicrob Agents Chemother 2002;46:3026-3030.
19. Edmiston CE, Krepel C, Kelly H, et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: Do we achieve therapeutic levels? Surgery 2004;136:738-747.
20. Itani KM, Wilson SE, Awad SS, et al. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med 2006;355:2640-2651.
21. Horan TC, Gaynes RP, Martone WJ, et al. CDC definitions of nosocomial surgical site infections, 1992: A modification of CDC definitions of surgical wound infections. Am J Infect Control 1992;20:271-274.
22. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985;4:213-226.
23. Smith RL, Bohl JK, McElearney ST, et al. Wound infection after elective colorectal resection. Ann Surg 2004;239:599-605.
24. Chen M, Nafziger AN, Drusano GL, et al. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother 2006;50:1222-1227.
25. Lipsky BA, Armstrong DG, Citron DM, et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): Prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005;366:1695-1703.
26. Lipsky BA, Sheehan P, Armstrong DG, et al. Clinical predictors of treatment failure for diabetic foot infections: Data from a prospective trial. Int Wound J 2007;4:30-38.